Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | RPA1 | P27694 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14664865 | 0.83 | SOS1 (0.44) | SOS1HTR2ASLC6A4KCNH2EGFR | |
| SCHEMBL522748 | 0.83 | PPARG (0.41) | HTR2ASLC6A4KCNH2MAPTKMT2A | |
| SCHEMBL4345160 | 0.79 | SOS1 (0.65) | SOS1HTR2ASLC6A4KCNH2EGFR | |
| SCHEMBL177743 | 0.79 | SOS1 (0.41) | SOS1HTR2ASLC6A4 | |
| SCHEMBL177501 | 0.79 | HSP90AA1 (0.47) | HTR2ASLC6A4KCNH2SMN1; SMN2HSD17B10 | |
| SCHEMBL3759344 | 0.76 | SOS1 (0.47) | SOS1HTR2ASLC6A4KCNH2EGFR | |
| SCHEMBL1042563 | 0.76 | MAPT (0.56) | SOS1HTR2ASLC6A4KCNH2EGFR | |
| SCHEMBL1529024 | 0.74 | NR4A1 (0.38) | SOS1MAPTSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL177568 | 0.74 | HTR2A (0.40) | HTR2ASLC6A4KCNH2RAB9AKMT2A | |
| SCHEMBL529160 | 0.74 | HSD17B10 (0.48) | MAPTSMN1; SMN2MAPK1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921299-B2 | Detergents having acceptable color | THE PROCTER & GAMBLE COMPANY (US) | 2014-12-30 | — | — | US | claimed |
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | claimed |
| US-12522813-B2 | Mannanase for formulations having pH 5-12 | BASF SE (DE) | 2026-01-13 | — | — | US | disclosed |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| CN-120077035-A | As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 | 阿斯利康(瑞典)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-114929676-B | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| EP-4482824-A1 | CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS | Guangdong Newopp Biopharmaceuticals Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| CN-118976029-A | Pharmaceutical composition for preventing or treating parkinson's disease or nonalcoholic steatohepatitis | 韩国化学研究院 | 2024-11-19 | — | — | CN | disclosed |
| CN-118975434-A | Organic light emitting device | 株式会社LG化学 | 2024-11-15 | — | — | CN | disclosed |
| US-5530005-A | THERAPY FOR SKIN DISORDERS, AIDS, IMMUNOSUPPRESION DISEASES | SYNTEX (U.S.A.) INC. (US) | 1996-06-25 | — | — | US | disclosed |
| US-5527827-A | ANTIASTHMATIC, ANTIALLERGIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROSST CANADA, INC. (CA) | 1996-06-18 | — | — | US | disclosed |
| WO-1996013491-A1 | BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1996-05-09 | — | — | WO | disclosed |
| WO-1996013500-A1 | BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1996-05-09 | — | — | WO | disclosed |
| EP-0691966-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5475003-A | Antiinflammatory agent, immunosuppressive, antiallergens, bronchodilators, analgens | SYNTEX (U.S.A.) INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5455252-A | Antiinflammatory agent, immunosuppressant, antiallergen, skin disorders, bronchodilator, analgesic | SYNTEX (U.S.A.) INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | disclosed |
| WO-1994022852-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | SOS1 1346/4885HTR2A 1313/4885SLC6A4 146/4885 |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | SOS1 1568/4885HTR2A 4165/4885SLC6A4 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.